[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digestive-system-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digestive-system-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,61,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":42,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099",false,"NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma",[43,44,45,46,47],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","RECRUITING","2025-12-25",{"date":51,"type":52},"2025-12-31","ACTUAL",{"date":54,"type":52},"2024-12-04",{"date":56,"type":21},"2027-09",{"name":58,"class":59},"RenJi Hospital","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100588338","real-world-study-on-nano-crystalline-megestrol-acetate-for-cachexia-in-tki-treated-advanced-digestive-tumors-100588338","NCT06940102","Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors","A Multicenter, Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in Patients With Advanced Digestive System Tumors Receiving TKI-Based Therapy","Inclusion Criteria:\n\n* Voluntarily sign a written informed consent (ICF).\n* Age ≥ 18 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy ≥ 3 months.\n* Histologically or cytologically confirmed locally advanced or metastatic digestive system tumors that are not amenable to curative treatment, according to the 8th edition TNM staging classification.\n* Not benefiting from local anticancer therapies such as surgery, local ablation, or chemoembolization, and planned to receive TKI-based anticancer treatment, which may be combined with chemotherapy or immunotherapy).\n* Meet the diagnostic criteria for pre-cachexia or cachexia (based on Fearon diagnostic criteria).\n* Good organ function determined\n\nExclusion Criteria:\n\n* Gastrointestinal obstruction.\n* Anorexia due to difficulty in eating caused by neurosis, mental illness, or pain.\n* Comorbidities such as severe cerebrovascular, cardiac, renal, or liver diseases.\n* Major surgery or trauma within the last month.\n* Allergy to any component of the investigational drug.\n* Other conditions deemed unsuitable by the investigator.",{"count":69,"type":21},120,"OBSERVATIONAL","This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.",[73,31,74,75,76],"Cachexia","Gastric Cancer","Colorectal Cancer","Hepatocellular Carcinoma",[78,79,80,81,82,83,84,31],"Megestrol Acetate","Nano-crystalline Megestrol Acetate","Targeted Therapy","Tyrosine Kinase Inhibitors","Prospective Studies","Observational Studies","Antineoplastic Agents","2025-04-15",{"date":87,"type":52},"2025-04-23",{"date":89,"type":52},"2025-03-12",{"date":91,"type":21},"2026-12",{"name":93,"class":94},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":60},"100533239","nutritional-psychological-intervention-and-vomit-free-management-on-survival-and-quality-of-life-in-advanced-gastrointestinal-tumors-100533239","NCT06223230","Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors","Inclusion Criteria:\n\n1. Age 18-75, male or female;\n2. Patients with advanced esophageal cancer, gastric cancer, liver cancer and colorectal cancer and other gastrointestinal tumors diagnosed by pathological histology or cytology;\n3. Expected survival ³ 8 weeks and able to receive long-term follow-up;\n4. Eastern Cooperative Oncology Group(ECOG)-Performance Status(PS) score of 0-2;\n5. First-line treatment receiving standard oncology treatment and nutritional psychological intervention and vomit-free management group (study group); first-line treatment receiving only standard oncology treatment group (control group);\n6. Voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n1. Other malignant tumors diagnosed within the previous 5 years, except for effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or effectively resected in situ cervical cancer or breast cancer;\n2. history of psychiatric illness prior to the diagnosis of the tumor\n3. patients who resist treatment\n4. patients with poorly controlled severe heart disease, liver or kidney insufficiency, severe anemia, multiple lymph node enlargement, leukopenia, etc;\n5. patients who are pregnant or have a pregnancy plan;\n6. patients who, in the judgment of the investigator, are not suitable for inclusion in this study.",{"count":103,"type":21},316,[24],"Aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone",[31,29],"2024-01-28",{"date":109,"type":52},"2024-01-30",{"date":111,"type":52},"2022-06-01",{"date":113,"type":21},"2026-06-30",{"name":115,"class":59},"Renmin Hospital of Wuhan University"]